Background
Nasopharyngeal carcinoma (NPC) is most prevalent in southeastern Asia [
1,
2], the histology of which is almost World Health Organization (WHO) types III (undifferentiated) [
3]. In contrast to other squamous cell carcinoma of the head and neck, NPC is characterized by a high tendency for metastatic dissemination [
4,
5]. About 5-8% of NPC patients are present with distant metastasis(es) at diagnosis, and 30 to 60% of locally advanced patients will develop distant metastasis(es) and die of disseminated disease [
2,
4,
6]. NPC with distant metastasis makes a very heterogeneous group, of which the post-metastatic survival can vary considerably ranging from weeks to years [
7‐
9].
The lung is a one of the most common organ to which distant metastasis can occur in NPC patients [
10,
11]. Hui et al reported that, compared with other metastatic patterns, those with lung metastasis(es) alone presented a significantly better overall survival [
7]. Others have reported up to 60 months disease-free survival in patients with solitary intrathoracic metastasis treated aggressively with combined therapy [
8,
12,
13]. Thus, we postulate that it may be associated with a unique biologic behavior in NPC patients with lung metastasis(es) alone. However, to our best knowledge, the mechanism behind the phenomenon and the precise predictive factors for intervention and prognosis of this group haven't been clearly identified.
To date, the role of chemotherapy is well established for metastatic NPC, but the objective response is still far from satisfied [
14‐
19]. Although several publications have shown in small cohorts that NPC patients with lung metastasis(es) alone may benefit from combined therapy, no data exists in larger patient cohorts [
8,
20‐
22]. We set out this retrospective study thought to add more evidences to help define the predictive factors of this group in a large cohort, and to facilitate the selection of the appropriate group to receive combined modality treatment for a better survival.
Methods
Patients
A database was prospectively established for the purpose of this analysis. Between 1993 and 2008, a total of 246 NPC patients with lung metastasis(es) (either present at diagnosis or at the first failure after receiving primary treatment) in Sun Yat-Sen University Cancer Center were consecutively enrolled. All the patients were pathologically confirmed NPC, and evaluated as complete remission for local-regional disease after primary treatment of radiotherapy with or without chemotherapy. Lung metastasis(es) was routinely determined by chest X-ray and/or computed tomography (CT). When both X-ray and/or CT were insufficient to confirm lung metastasis(es), the pathological confirmation by biopsy was then carried out. Patients who have preexisting malignant disease or a second primary tumor, or those with extra-pulmonary metastases were excluded. The study was approved by the medical ethics committee of Sun Yat-Sen University Cancer Center.
The stages of the disease were classified according to the Tumor-Node-Metastasis system (NCCN 2007). The differentiation status and histotype of the disease were classified according to the World Health Organization (WHO) classification for NPC. The characteristics of the 246 NPC patients enrolled in the study are shown in Table
1.
Table 1
Characteristics of 246 NPC patients with lung metastasis(es) alone at diagnosis or the first failure.
Age (years)
a
| |
≤ 45 | 130 (52.8) |
> 45 | 116 (47.2) |
Gender | |
Male | 196 (79.7) |
Female | 50 (20.3) |
Histology | |
WHO type I | 3 (1.2) |
WHO type II | 7 (2.8) |
WHO type III | 236 (96.0) |
EBV VCA-lgA
b
| |
≤ 320:1
c
| 100 (40.7) |
> 320:1 | 70 (28.5) |
EBV EA-lgA
b
| |
≤ 40:1
d
| 112 (45.5) |
> 40:1 | 58 (23.6) |
UICC T classification | |
T1-2 | 97 (39.4) |
T3-4 | 149 (60.6) |
UICC N classification | |
N0 | 41 (16.7) |
N1-3 | 205 (83.3) |
UICC M classification | |
M0 | 201 (81.7) |
M1 | 45 (18.3) |
Lung metastasis
| |
DFI (years) | |
≤ 1 | 92 (37.4) |
1-3 | 86 (35.0) |
> 3 | 68 (27.6) |
Metastasis site | |
Unilateral | 118 (48.0) |
Bilateral | 128 (52.0) |
Metastasis number | |
Solitary | 82 (33.3) |
Multiple | 164 (66.7) |
Metastasis size (cm)
e
| |
≤ 2 | 147 (59.8) |
> 2 | 99 (40.2) |
Treatments
For patients presented with lung metastasis(es) at diagnosis (M1), 6 cycles of chemotherapy with Cisplatin/5-fluorouracil (PF) regimen were administered before concurrent chemoradiotherapy. The PF chemotherapy regimen consisted of 20 to 30 mg/m2 cisplatin intravenous bolus on days 1 to 3 and 800 to 1,000 mg/m2/24 hours continuous intravenous infusion of 5-fluorouracil on days 1 to 4 of each cycle, repeated every 21 days. For those with M0 stage, radical radiotherapy or concurrent chemoradiotherapy with the Cisplatin-based regimen were performed for early stage or locally advanced NPC patients, respectively. During the treatments, new metastatic lesions were found in none of the patients, and all of them received external beam radiotherapy by a 6 MV linear accelerator. All patients had planning computerized tomography of the head and neck performed with patient in the treatment position. Computerized tomography-assisted radiation treatment planning was obtained before the initiation of radiotherapy. A dose of 68-70 Gy/6.5-7 weeks was normally given to the primary tumor. A does of 64-66 Gy/6-7 weeks to the involved neck nodes, whereas the does for node-negative neck was 50 Gy/5-5.5 weeks. Therapeutic efficacy was assessed 3-6 months after the primary treatment, according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
The patients were followed up in the out-patient clinics, where diagnostic examinations consisting of nasopharyngeal and neck magnetic resonance imaging (MRI), chest x-ray and/or CT, abdominal ultrasonography and bone scan were performed every 3-6 months for the first 3 years and finally annually thereafter to detect local recurrence and/or metastasis. For those present with lung metastasis(es) alone as the first failure, 4-6 cycles of palliative chemotherapy with DDP based regimen was administered. Local therapies such as surgery or radiotherapy served as options for those still with metastatic lesions limited in lung after chemotherapy.
Statistical analysis
Statistical analysis was performed using SPSS 13.0 package (SPSS Standard version 13.0, SPSS Inc, Chicago, IL). Chi-square test was used to compare the difference of categorical variables. Disease-free interval (DFI) was calculated from the completion of initial treatment to the time when lung metastasis(es) was identified. Overall survival (OS) or post-metastasis survival (PMS) was defined as from the date of completing the initial treatment or the date of lung metastasis(es) identified to the date of death or the last follow-up, respectively. The survival curves were calculated by the Kaplan-Meier method and compared using the log-rank test. Multivariate survival analysis was performed on all parameters that were found significant on univariate analysis using the Cox regression model. P values < 0.05 were considered significant.
Discussion
Although the prognosis of metastatic NPC is still quite poor, it has been well accepted that the survival of metastatic NPC can be highly variable and long-term survival is possible in some patients [
7‐
9,
17,
23,
24]. Particularly, NPC patients with lung metastasis(es) alone were reported as a distinctive group with a good prognosis compared with other type of metastasis [
7,
8]. Thus, the identification of prognostic factors of this group will be of great importance from both a therapeutic and research point of view. In this study, we presented the long-term outcome and prognostic indicators of survival in a large cohort of NPC patients with lung metastasis(es) alone.
The 3-year OS and PMS reported in metastatic NPC patients with different series were less than 40% and 20%, respectively [
9]. In the present study, we reported a much better prognosis in 246 NPC patients with lung metastasis(es) alone, with a 3-year OS of 67.8% and a 3-year PMS of 34.3%. Our results concurred closely with another study of lung metastasis of NPC in Hong Kong that NPC patients with lung metastasis(es) alone (
n = 41) appeared to have a distinctively better prognosis, with a hazards ratio (HR) of 0.41 compared with other types of metastasis(es) [
7]. In other studies, intrathoracic metastasis(es) (lung and/or mediastinal nodes) was considered as a good prognostic factor in metastatic NPC [
8,
20,
21]. However, to our knowledge, no literature has identified the precise predictive factors for the prognosis in this specific group.
It was demonstrated in our study that young age (≤ 45 years), long DFI (> 1 year), unilateral metastasis, solitary metastasis and combined therapy were good prognostic factors in terms of both OS and PMS based on univariate survival analysis, while only young age, long DFI and combined therapy were found to be independent good prognostic factors of OS according to multivariate analysis. These factors have also been indicated in other studies as good prognosis in patients with lung metastasis(es) from head and neck cancers [
4,
11,
25,
26]. For young age, we cannot explain clearly why it is a good prognostic factor, but it may be related to the significant association between young age and long DFI found in the present study. In another hand, young patients usually have better performance status to tolerate the side effect of aggressive combined therapy, and react positively towards the treatment than old patients, and thus they are more likely to accept the treatment after the discovery of lung metastasis(es) than elderly patients.
DFI has long been identified as an important prognostic factor for patient outcome, but the significant cutoff points of DFI are still uncertain according to the literatures [
4,
8,
11,
27‐
29]. In NPC, Teo et al reported that the OS of patients presenting with distant metastasis(es) abinitio (M1, DFI = 0) is much worse than those developing distant metastasis(es) after primary radiotherapy (M0, DFI > 0) [
8]. In our study, DFI = 0 (M1) was also found to a poor prognostic factor of OS of NPC patients in univariate analysis, but there was no difference of PMS between DFI = 0 months (M1) and DFI > 0 months (M0) groups. Another reported cutoff of DFI < 6 months, which was identified by Ong et al as an independent prognostic factor of PMS in metastatic NPC; while in another study conducted by Khanfir et al, no difference of PMS between groups with DFI ≤ 6 months and DFI > 6 months was observed [
4,
11]. It's believed that different types of metastatic NPC might correspond with different significant cutoff points of DFI, which might partly contribute the variances of DFI cutoff points reported in the literatures. In our study, we proposed that DFI ≤ 1 year, 1-3 years and > 3 years were the proper cutoff values to distinguish both the OS and PMS in NPC patients with lung metastasis(es) alone. Patients with young age (≤ 45 years), early T classification, and without lymph node metastasis would be likely to have longer DFI.
Treatment modality is another important independent prognostic factor in our study. We demonstrated that, compared to single chemotherapy, combined therapy improved both the OS and PMS for NPC patients with lung metastasis(es) alone. Geara et al reported similar results in 103 metastatic NPC patients who treated with radiotherapy and chemotherapy (2 yeras-OS, 45%) for their metastases had a significantly better survival than those received no treatment (2 years-OS, 14%) or single chemotherapy (2 years-OS, 18%,
P = 0.001) [
22]. In addition, some long-term survivors aggressively treated with pulmonary metastasectomy in combination with chemotherapy were also reported in NPC patients with intrathoracic metastasis(es) alone [
10,
12,
13,
20,
28‐
30]. Collectively, these data suggests an indication for combined therapy in selected metastatic NPC patients. Thus, it seems necessary to further evaluate which subgroup of patients would benefit from it. In our stratified survival analysis, treatment modality was found to have improved the outcome of patients with DFI greater than 1 year, but not those with DFI less than 1 year.
There are several limitations to our study. Our study is a retrospective study, relied exclusively on a single-institutional database. A larger scale, prospective, multi-center study is needed to confirm our results.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
XC performed the statistical analysis, drafted the manuscript and participated in the sequence alignment. LRH participated in the design of the study and participated in the sequence alignment. FYX participated in the sequence alignment. YFC carried out data acquisition. ZSW conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.